Diabetic nephropathy (DN) is the most common pathology contributing to the development of chronic
kidney disease (CKD). DN caused by hypertension and unmitigated inflammation in diabetics, renders
the kidneys unable to perform normally, and leads to renal fibrosis and organ failure. The increasing global
prevalence of DN has been directly attributed to rising incidences of Type II diabetes, and is now the
largest non-communicable cause of death worldwide. Despite the high morbidity, successful new treatments
for DN are lacking. This review seeks to provide new insight on emerging clinical candidates under
investigation for the treatment of DN.